Proceedings of the 51st Hawaii International Conference on System Sciences | 2018

Low-energy Bluetooth for detecting real-world penetrance of bystander
naloxone kits: a pilot study
Jeffrey T. Lai
University of Massachusetts
Medical School
jeffrey.lai@umassmemorial.org

Brittany P. Chapman
University of Massachusetts
Medical School
brittany.chapman@umassmed.edu

Edward W. Boyer
Harvard Medical School
eboyer@bwh.harvard.edu

Abstract
Opioid overdose is a growing public health
emergency in the United States. The antidote
naloxone must be administered rapidly after opioid
overdose to prevent death. Bystander or “take-home”
naloxone programs distribute naloxone to opioid
users and other community members to increase
naloxone availability at the time of overdose.
However, data describing the natural history of takehome naloxone in the hands of at-risk individuals is
lacking. To understand patterns of naloxone uptake
in at-risk users, we developed a smart naloxone kit
that uses low-energy Bluetooth (BLE) to
unobtrusively detect the transit of naloxone through a
hospital campus. In this paper, we describe
development of the smart naloxone kit and results
from the first 10 participants in our pilot study.

1. Introduction
Heroin overdose deaths have more than doubled
from 2000 to 2014, triggering the growth of harmreduction programs aimed at 1) training non-medical
personnel to recognize and respond to opioid
overdoses, and 2) dispensing overdose rescue kits
containing naloxone, the antidote for opioid
overdose, to at-risk individuals and their friends and
family from community and emergency department
sites.[3,6,9,12,15] Despite the growth of “bystander”
naloxone distribution programs and observations of a
decrease in opioid overdose deaths in communities
where they have been implemented, overdose deaths
continue to increase.[16] The Centers for Disease
Control (CDC) reported 33,091 individuals died from
opioid overdose in 2015, a 15.6% increase since
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2014.[13] Unfortunately, rigorous data delineating
what happens to these overdose rescue kits once
distributed to heroin users are lacking. Understanding
the patterns of naloxone distribution and use in a
community through advanced technology-based
monitoring can guide strategies to improve naloxone
distribution programs.[8]
The introduction of a technology-based
monitoring system that can easily integrate into a
standard overdose rescue kit provides the ability to
directly ascertain the real-time location of naloxone
rescue kits. By providing insights into the patterns of
naloxone distribution and use in a community, these
technology-enabled naloxone kits can provide
valuable information on real-world uptake of
bystander naloxone by active heroin users and help to
optimize
naloxone
distribution
programs.
Furthermore, this information can guide the
development of real-time mobile technology
interventions for these at-risk populations.
Discovering the fate of naloxone rescue kits can
be accomplished through unobtrusive low-energy
Bluetooth (BLE) technology. Similar to monitoring
medical equipment or patients as they transit through
a hospital system, BLE technology incorporated into
naloxone rescue kits dispensed from an emergency
department (ED) setting can provide insight into the
uptake of naloxone kits by heroin users and the
availability of these kits for use in the
community.[10,14]
In this pilot study, we deployed a naloxone
rescue kit with an integrated BLE beacon (“smart
naloxone kit”) to help determine the community
penetrance of ED distributed naloxone.

2. The smart naloxone kit
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The “smart naloxone kit” consists of a standard
Food and Drug Administration (FDA)-approved
intranasal naloxone syringe combined with a BLE
identification tag. As smart naloxone kits exit the
emergency department, they enter detection zones of
strategically placed BLE readers which collect and
log the transit of smart naloxone kits through specific
locations on a hospital campus (Figures 1 & 2). Data
from BLE readers indicate the proportion of smart
naloxone kits that become available for use in the
community.

2.1. Low-energy
beacons

Bluetooth

to BLE but employing slightly different frequencies,
have shown no alteration in the stereochemistry or
molecular
composition
of
xenobiotics.[1,2]
Additionally, RFID is increasingly utilized in
pharmaceutical manufacturing, underscoring the
safety of using this technology near xenobiotics.[7]

identification

BLE beacons (36mm x 23mm x 4mm) powered
by an integrated battery actively transmit a preprogrammed unique identifier code. BLE beacons
have a battery life of three months. Beacons transmit
pre-programmed identifiers using 2.4 gigahertz
(GHz) radiofrequency waves, the same frequency
employed by most WiFi routers and cordless
telephones.[5] By using a set 2.4GHz frequency,
BLE beacons avoid interference from conventional
medical equipment like intravenous pumps, cardiac
pacemakers and insulin pumps.

2.2. Low-energy Bluetooth systems do not
affect biological systems
Theoretical concerns have been raised regarding
the ability of radiofrequency waves to alter the
molecular
composition
and
efficacy
of
xenobiotics.[2] We believe this concern is
unfounded.
Studies
exposing
radiofrequency
identification (RFID) systems, a similar technology

2.3. Low-energy Bluetooth readers
BLE readers, approximately the size of a
wireless router, serve as a relay station for
information transmitted by BLE beacons: when a
BLE beacon enters the detection radius of a BLE
reader, the beacon transmits pre-recorded data
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including the specific beacon identification number.
This information is captured by the BLE reader and
securely stored on its on-board, encrypted memory.
The BLE reader also transmits BLE beacon transit
data to a secure cloud-based interface. BLE readers
have a detection radius of 20 meters and can
penetrate clothing and metal, therefore allowing
detection of smart naloxone kits carried in pockets,
cars, or buses. The readers are powered by
rechargeable batteries that last for 24 hours, allowing
them to be affixed to telephone poles or light posts
without a grounded power source. The readers are
housed in locked weatherproof, shockproof casings
built to military specification (Figure 2).

2.4. BLE reader placement
BLE readers were positioned at strategic
locations around the hospital campus, corresponding
to the avenues of pedestrian and vehicular egress that
patients utilize when they are discharged from the
ED: the ED registration area, the ambulance bay exit,
the pedestrian walkway to the bus stop, and the two
main roads for automobile traffic. These locations
were chosen to capture participants as they exited the
hospital campus 1) by walking or driving along the
main roads, 2) by ambulance, 3) by public transit
(Figure 3).

By selecting BLE readers with adequate range to
cover major road intersections and power to penetrate
cars, we can detect the transit of smart naloxone kits
off of a hospital campus. This approach is highly
scalable—rapid deployment of BLE readers
throughout a community in response to an escalating
heroin epidemic can help public health officials and
researchers discover hotspots of naloxone as a marker

for heroin use, and target interventions to these key
geographic areas.

3. Methods
3.1. Design considerations
The smart naloxone kit was designed to be
discreet to maximize acceptance by heroin users.
Placing unobtrusive BLE tags within the carton
containing the syringe, ampule and nasal atomizer
ensures the ability to locate smart naloxone kits
without obvious indicators that kits are being tracked.
Affixing the monitoring device to a critical
component such as the naloxone syringe was
considered to address the scenario where a participant
might keep the medication and atomizer while
discarding the box prior to leaving the hospital, but
this was not done out of concern that it might
interfere with the efficient delivery of naloxone in an
emergency situation.
Similarly, BLE readers were selected because
they provided the necessary combination of detection
range and penetrance around metal and human bodies
(which can interfere with the performance of other
modalities such as RFID), allowing for the detection
of tagged kits carried in various ways, including in
pockets, bags, cars, or buses.
Additionally, using advanced technology to
detect devices carried by patients with active drug
use may pose ethical concerns.[11] The smart
naloxone kit does not track patients continuously.
Instead, it utilizes a BLE tag that transmits a unique 6
character identification code that is detected by a
compatible BLE reader. Thus, the BLE system does
not provide continuous location data; rather it
captures discrete episodes of movement through BLE
reader detection zones.
Although the system does not continuously track
patients, security remains an important consideration.
Radiofrequency ID systems such as BLE can be
penetrated through passive eavesdropping, signal
jamming, or reader tampering.[11] Several methods
are employed to ensure the security of the BLE
system. First, BLE utilizes advanced encryption
technologies, the same standard used by the US
government.[5] Second, rather than using patient
identifiers such as name, birthdate, or medical record
number, the BLE tag utilizes the previously
mentioned 6 character code to identify itself to a BLE
reader, minimizing any threat to privacy or
confidentiality should the BLE system be
compromised. Third, once detected by the reader, the
BLE tag identifier is transmitted via secure WiFi or
cellular hotspot connection to a secure password
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protected interface; alternatively, if no internet
connection is available, the BLE tag information is
stored locally on the reader using encrypted internal
storage until such a time that an internet connection is
available. Finally, careful selection of BLE reader
placement prevents interference from other devices
utilizing similar radiofrequency transmissions, and
physical security measures such as locks and cables
minimize tampering with the devices.

3.2. Technology acquisition and verification
BLE beacons (Visybl AssetBeacons) and readers
(Visybl CloudNodes) were purchased from the
manufacturer (Visybl Inc., Germantown, MD, USA).
Field testing was performed using BLE readers
positioned around the hospital campus, and BLE
beacons in various configurations to simulate real-life
situations in which a smart naloxone kit might be
carried (e.g. in medication cartons, in shirt and pants
pockets, inside a moving vehicle). The author (JL)
carried a BLE beacon through detection zones for all
readers to ensure reliable signal capture.

3.3. Study design
This was a prospective pilot study utilizing a
convenience sample of participants presenting to the
ED with a heroin-related complaint. Participants were
eligible for the study if they were 18 years of age or
older, English-speaking, able to provide written
informed consent, and in possession of a mobile
phone with text messaging capability. Potential
subjects were excluded if they were pregnant,
prisoners or in police custody, or presenting with a
primary psychiatric complaint.
Participants were enrolled, provided written
consent, and underwent a standardized training
session on using naloxone and the functionality of the
smart naloxone kit. Consenting participants were
given a brief training on recognizing signs of heroin
and opioid overdose in addition to the assembly and
operation of the smart naloxone kit, in accordance
with validated methods of naloxone teaching
(prescribetoprevent.com). Next, participants were
given an overview of the BLE technology utilized in
the kit. The individual BLE beacon was activated,
verified to be operational, and sealed in the naloxone
kit with double sided tape. Contact information was
obtained from participants, including personal phone
number and phone number of a friend or family
member, to maximize our ability to contact subjects
for follow up.
As participants departed from the ED, transit of
the smart naloxone kit off the hospital campus was

detected by the BLE readers and accessed by batch
download using a secure cloud-based interface and
recorded by study staff.
Subjects were contacted via text message to
confirm accuracy of the technology on days 7, 10,
and 13. If there was no response, subjects were
contacted via phone call on days 7 and 10. If there
was no response to these phone calls, then subjects’
alternate contacts were called. If no response from
subjects or alternate contacts at 14 days, the subject
was considered lost to follow up.
The primary outcome for this study was
demonstrating the feasibility of utilizing a BLE
system to observe the transit of naloxone off a
hospital campus. Secondary outcomes included
observing the number of kits leaving the hospital
campus and whether these kits were utilized by
participants.

4. Results
During the study period, a total of 102
individuals presented to the ED with a heroin
overdose or heroin-related complaint. Of these, 10
individuals were consented, and no individuals
declined participation. Ten individuals completed the
study over the 3-month study period. Median age was
29 years, ten identified as Caucasian, nine
participants identified as male, and one participant
identified as female. Seven presented to the ED after
a heroin overdose while three presented after a
heroin-related complaint (Table 1).
Table 1. Participant demographics. OD
denotes overdose.
Triage
ID
Age
Sex
Race
Complaint
39

M

White

Withdrawal sx

24

M

White

OD

20

M

White

OD

28

M

White

OD

31

M

White

Detox

29

M

White

OD

29

M

White

Eval

29

M

White

Heroin OD

28

M

White

OD

29

F

White

OD
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4.1. Smart
distribution

naloxone

kit

uptake

and

All 10 individuals accepted the smart naloxone
kit and were trained to recognize signs of an opioid
overdose and administer naloxone. 70% of smart
naloxone kits (N=7) were detected by BLE readers
positioned at egress points from the hospital campus.
Two of the participants whose smart naloxone kits
were detected by the ED ambulatory exit reader but
not by the readers positioned along the egress paths
reported during follow-up that they carried the smart
naloxone kit off campus (Figure 4). This was likely
due to technical errors in which the readers were not
powered on. Of the four participants we successfully
contacted, one reported having utilized the smart
naloxone kit to reverse an opioid overdose.
Unfortunately, 60% of participants (N=6) were lost to
follow up.

retention through a hospital campus. This pilot
provides a template for mini smart naloxone kit
systems to be deployed in conjunction with new or
existing naloxone distribution programs to assess the
actual uptake of naloxone. Expansion of these
concepts could lead to strategic placement of BLE
readers around known overdose locations in a city to
determine if distributed naloxone first moves out of
the naloxone distribution site and if the distributed
kits are found in areas with overt overdose.
Engaging heroin users to understand factors
leading to acceptance or non-acceptance of advanced
monitoring devices is essential in the development of
future iterations of smart naloxone kits.[4] Successful
deployment of a smart naloxone distribution program
is likely contingent upon actively involving heroin
users in their design and providing reassurances that
privacy (e.g. location data not shared with law
enforcement) is held paramount.

5.1. Limitations

5. Discussion
Our data shows that a majority of individuals
accept and carry ED distributed naloxone off a
hospital campus and into the community. A majority
of participants carried the smart naloxone kits with
them on discharge from the ED, suggesting that
heroin users recognized the dangers of overdose,
were willing to carry naloxone, and were willing to
use smart naloxone kits to inform us about their
patterns of naloxone uptake. This pilot study
demonstrates that the smart naloxone kit is an
acceptable and feasible platform to improve
understanding of naloxone uptake and ultimately
acceptance among individuals with active substance
use.
Our smart naloxone kits were able to provide
passively generated evidence of naloxone uptake and

Although our concept is highly scalable, it has
several limitations. Our pilot study was aimed at
assessing feasibility of using BLE to detect naloxone
as it exits the site of distribution from our ED at a
single hospital campus. However, this study phase is
crucial to determining if patients will accept this
technology and distribute it throughout an urban area.
Further studies will require municipal participation to
place BLE readers at additional locations, expanding
the potential detection of smart naloxone kits in our
community.
Regrettably, we were unable to contact six
participants: phone numbers from five participants
either were disconnected or were unanswered, and
one participant was unable to be reached due to
constraints of his treatment program.

5.2. Future directions
BLE labeled naloxone provides a system that is
easily and quickly deployable that can be leveraged
to respond to the rising opioid epidemic across the
United States. An advantage of utilizing BLE-based
tracking platform is that Bluetooth technology is
ubiquitous: nearly all smartphones are equipped with
Bluetooth radios and can functionally serve as BLE
readers. Thus, any Bluetooth-enabled mobile phone
can be set up to detect our smart naloxone kit. This
“crowdsourcing” of BLE tag detection offers a costeffective method to vastly expand the ability to detect
a smart naloxone kit in an urban environment where
smartphones are omnipresent.
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6. Conclusion

66.

A smart naloxone kit comprised of BLE-labeled
nasal naloxone syringe and strategically placed BLE
readers can provide insight into natural uptake
patterns of naloxone among individuals at risk for
heroin overdose. This information will allow for
improvement
in
planning
community-based
interventions to prevent deaths from opioid overdose.
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